Noa Gonen

Dr. Noa Gonen


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2017 in Reproductive Biology and Endocrinology
Verified
Journal Article
Open access
PDF file
JHJigal Haas
Jigal Haas
RBRawad Bassil
Rawad Bassil
JMJim Meriano
Jim Meriano
NSNivin Samara
Nivin Samara
EBEran Barzilay
Eran Barzilay
RCRobert F. Casper
Robert F. Casper
For the last year we have been treating normal responders with gonadotropins and letrozole during the whole stimulation in order to improve response to FSH by increasing the intrafollicular androgen concentration, and to reduce circulating estrogen concentrations. The aim of this study was to compare the IVF outcome of normal responders treated with letrozole and gonadotropins during ovarian stimulation with patients treated with gonadotropins only. A single centre retrospective cohort study of 174 patients (87 in each group). The age of the patients was comparable between the groups. Estradiol levels were significantly higher in the control group (6760 pmol/L vs. 2420 pmol/L respectively, p < 0.01), and the number of follicles ≥15 mm at the trigger day was significantly lower in the control group (7.9 vs. 10, p = 0.02). The number of retrieved oocytes (10 vs. 14.5, p < 0.01), MII oocytes (7.9 vs. 11.2, p < 0.01) and blastocysts (2.7 vs. 4.0, p = 0.02) was significantly higher in the study group. We found no significant differences in the cumulative pregnancy outcome between the two groups (65.2% vs 58.3% p = NS). We conclude that co-treatment with letrozole improves the IVF outcome in normal responders in terms of increased number of blastocysts obtained without increasing the pregnancy rate or the risk of OHSS.

29 May 2018 in Reproductive Biology and Endocrinology
Verified
Journal Article
Open access
PDF file
JHJigal Haas
Jigal Haas
RBRawad Bassil
Rawad Bassil
NGNoa Gonen
Noa Gonen
JMJim Meriano
Jim Meriano
AJAndrea Jurisicova
Andrea Jurisicova
RCRobert F. Casper
Robert F. Casper
Previous studies have shown that androgens, in addition to serving as precursors for ovarian estrogen synthesis, also have a fundamental role in primate ovarian follicular development by augmentation of FSH receptor expression on granulosa cells. Recent studies have shown that aromatase inhibitor, letrozole, improves ovarian response to FSH in normal and poor responder patients, possibly by increasing intraovarian androgen levels. Studies in mice also showed an effect of letrozole to increase pigment epithelium-derived factor (PEDF) and to lower vascular epithelial growth factor (VEGF), which might be expected to reduce the risk of ovarian hyperstimulation syndrome (OHSS) with stimulation. The aim of this study was to compare the VEGF and PEDF levels in the follicular fluids of normal responders treated with letrozole and gonadotropins during the ovarian stimulation with patients treated with gonadotropins only. A single center, prospective clinical trial. We collected follicular fluid from 26 patients, on a GnRH antagonist protocol, dual triggered with hCG and GnRH agonist. The patients in one group were co-treated with letrozole and gonadotropins during the ovarian stimulation and the patients in the other group were treated with gonadotropins only. VEGF, PEDF, estrogen, progesterone and testosterone levels were measured by ELISA kits. The age of the patients, the total dose of gonadotropins and the number of oocytes were comparable between the two groups. In the follicular fluid, the estrogen levels (2209 nmol/l vs. 3280 nmol/l, p = 0.02) were significantly decreased, and the testosterone levels (246.5 nmol/l vs. 40.7 nmol/l, p < 0.001) were significantly increased in the letrozole group compared to the gonadotropin only group. The progesterone levels (21.4 μmol/l vs. 17.5 p = NS) were comparable between the two groups. The VEGF levels (2992 pg/ml vs. 1812 pg/ml p = 0.02) were significantly increased and the PEDF levels (9.7 ng/ml vs 17.3 ng/ml p < 0.001) were significantly decreased in the letrozole group. Opposite to observations in the mouse, we found that VEGF levels were increased and PEDF levels were decreased in the follicular fluid in patients treated with letrozole during the stimulation cycles. Further investigation is required to determine if patients treated with letrozole during the IVF stimulation protocol are at increased risk for developing OHSS as a result of these findings.

24 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MFMatan Friedman
Matan Friedman
ASAmit Slouk
Amit Slouk
NGNoa Gonen
Noa Gonen
LGLaura Guzy
Laura Guzy
YPYael Ganor Paz
Yael Ganor Paz
IKIlia Kleiner
Ilia Kleiner
Background/Objectives: Large Language Models (LLMs), including ChatGPT-4 and Gemini, are increasingly incorporated into clinical care; however, their reliability within maternal–fetal medicine (MFM), a high-risk field in which diagnostic and management errors may affect both the pregnant patient and the fetus, remains uncertain. Evaluating the alignment of AI-generated case management recommendations with those of MFM specialists, emphasizing accuracy, agreement, and clinical relevancy. Study Design and Setting: Cross-sectional study with blinded online evaluation (November–December 2024); evaluators were blinded to responder identity (AI vs. human), and case order and response labels were randomized for each evaluator using a computer-generated sequence to reduce order and identification bias. Methods: Twenty hypothetical MFM cases were constructed, allowing standardized presentation of complex scenarios without patient-identifiable data and enabling consistent comparison of AI-generated and human specialist recommendations. Responses were generated by ChatGPT-4, Gemini, and three MFM specialists, then assessed by 22 blinded board-certified MFM evaluators using a 10-point Likert scale. Agreement was measured with Spearman’s rho (ρ) and Cohen’s (κ); accuracy differences were measured with Wilcoxon signed-rank tests. Results: ChatGPT-4 exhibited moderate alignment (mean 6.6 ± 2.95; ρ = 0.408; κ = 0.232, p < 0.001), performing well in routine, guideline-driven scenarios (e.g., term oligohydramnios, well-controlled gestational hypertension, GDMA1). Gemini scored 7.0 ± 2.64, demonstrating effectively no consistent inter-rater agreement (κ = −0.024, p = 0.352), indicating that although mean scores were slightly higher, evaluators varied widely in how they judged individual Gemini responses. No significant difference was found between ChatGPT-4 and clinicians in median accuracy scores (Wilcoxon p = 0.18), while Gemini showed significantly lower accuracy (p < 0.01). Model performance varied primarily by case complexity: agreement was higher in straightforward, guideline-based scenarios and more variable in complex cases, whereas no consistent pattern was observed by gestational age or specific clinical domain across the 20 cases. Conclusions: AI shows promise in routine MFM decision-making but remains constrained in complex cases, where models sometimes under-prioritize maternal–fetal risk trade-offs or incompletely address alternative management pathways, warranting cautious integration into clinical practice. Generalizability is limited by the small number of simulated cases and the use of hypothetical vignettes rather than real-world clinical encounters.